Kurma Partners has reached over EUR 83 million with the closing of its fund Kurma Diagnostics 2 (KDx2), exceeding its inital target. KDx2 is backed by well-known investors, including existing and new investors.
After a first closing in 2020 at EUR 50 million, the KDx2 fund is now ahead of its initial target at EUR 83 million. The new generation Kurma Diagnostics fund continues its predecessor’s investment strategy with minority stakes in European companies specialising in areas like developing digital therapies, advanced diagnostic tools and smart and connected medical objects.
With the support of its long-time and new investors, KuKDx2 aims to build a portfolio of about 15 innovative companies in the European Union. After the first closing in August 2020, KDx2 has invested in four French companies Mila, Arkhn, Smartcatch and Omnidoc.
Kurma Partners has been financing innovative biotech and medical technology companies throughout Europe since 2009. In early 20219, the venture capitalist opened its own office in Munich.
With more than EUR 500 million in assets under management and more than 45 investments made since its launch in 2009, Kurma Partners has developed strong expertise in financing healthcare innovation, from pre-seed to growth capital.
The existing investors of the Kurma Diagnostics 2 fund are the European Investment Fund (EIF) with the support of InnovFin Equity and of the European Guarantee Fund (EGF), Fonds national d’amorçage 2 (the French Seed Fund), managed by Bpifrance on behalf of the French State, BNP Paribas. The new investors include three Belgian funds, SFPI-FPIM, Noshaq and Sambrinvest, in addition to Eurazeo, which recently increased its stake in the management company.